Na Tosha Gatson, MD
Neurological Surgery · Phoenix, AZNPI 1790910560
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,913 of the $103,499 with a category attached, or 65.6%. 9 manufacturers reported payments, led by Novocure Inc. at 49.1% of the total. 2025 is the largest year on record at $37,552, 4.2 times the $8,930 reported in 2019.
Across 118 payments — averaging $877.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$51K
- Menarini Silicon Biosystems, Inc.$31K
- GT Medical Technologies, Inc$21K
- Monteris Medical Corporation$437
- Bayer$295
- Tesaro, Inc.$61
- plus $103 from 3 others
Across 1 payment — averaging $18,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$18K
What the payments were for
- Consulting fees$67,91366%
- Speaking & faculty fees$15,01515%
- Travel & lodging$15,14315%
- Food & beverage$5,3675%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 49 | $50,818 |
| Menarini Silicon Biosystems, Inc. | 20 | $31,107 |
| GT Medical Technologies, Inc | 39 | $20,678 |
| Monteris Medical Corporation | 3 | $437 |
| Bayer | 3 | $295 |
| Tesaro, Inc. | 1 | $61 |
| AstraZeneca | 1 | $58 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Seagen Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$31,044
- CELLSEARCH$30,950
- GammaTile$20,097
- Oncology$12,422
- Neuroblate$437
- Vitrakvi$221
How this compares
$103,499 in reported general payments places this provider in the 85th percentile of 173 neurological surgery providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 17 | $1,982 |
| Levetiracetam | 30 | $910 |
| Memantine Hcl | 12 | $472 |
| Dexamethasone | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Phoenix
- Robert SpetzlerPhoenix$12.8M
- Juan UribePhoenix$6.7M
- Stephen PapadopoulosPhoenix$6M
- Volker SonntagPhoenix$2M
- Jay TurnerPhoenix$1.2M
- Michael LawtonPhoenix$761K
- Bryan LeePhoenix$441K
- Randall PorterPhoenix$410K
- Joseph ZabramskiPhoenix$381K
- Francisco PoncePhoenix$292K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.